Do analysts prefer NNNN or LNTH?

Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.09%. Given Lantheus' stronger consensus rating and higher possible upside, analysts plainly believe Lantheus is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lantheus 0 Sell rating(s) 9 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.36

Which has better valuation & earnings, NNNN or LNTH?

Lantheus has higher revenue and earnings than Anbio Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 176.56 $6.40M N/A N/A Lantheus $1.54B 4.26 $233.56M $4.14 24.38

Do analysts prefer XENE or NNNN?

Xenon Pharmaceuticals presently has a consensus price target of $77.13, indicating a potential upside of 21.74%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Xenon Pharmaceuticals is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.00 Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, XENE or NNNN?

Anbio Biotechnology has higher revenue and earnings than Xenon Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xenon Pharmaceuticals $7.50M 816.67 -$345.91M -$4.74 N/A Anbio Biotechnology $8.65M 176.56 $6.40M N/A N/A

Is XENE or NNNN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -49.52% -46.72% Anbio Biotechnology N/A N/A N/A

Do analysts prefer PTCT or NNNN?

PTC Therapeutics currently has a consensus target price of $98.09, suggesting a potential upside of 33.80%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe PTC Therapeutics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 2 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.64 Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, PTCT or NNNN?

PTC Therapeutics has higher revenue and earnings than Anbio Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PTC Therapeutics $1.73B 3.54 $682.64M -$0.58 N/A Anbio Biotechnology $8.65M 176.56 $6.40M N/A N/A

Do analysts prefer BLTE or NNNN?

Belite Bio presently has a consensus price target of $203.00, suggesting a potential upside of 24.50%. Given Belite Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Belite Bio is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Belite Bio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, BLTE or NNNN?

Anbio Biotechnology has higher revenue and earnings than Belite Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.53 N/A Anbio Biotechnology $8.65M 176.56 $6.40M N/A N/A

Is BLTE or NNNN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Anbio Biotechnology N/A N/A N/A

Do analysts recommend CGON or NNNN?

CG Oncology currently has a consensus target price of $83.18, suggesting a potential upside of 10.76%. Given CG Oncology's stronger consensus rating and higher probable upside, equities analysts clearly believe CG Oncology is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.71 Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, CGON or NNNN?

Anbio Biotechnology has higher revenue and earnings than CG Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,639.56 -$160.99M -$2.33 N/A Anbio Biotechnology $8.65M 176.56 $6.40M N/A N/A

Anbio Biotechnology (NNNN) Competitors

$10.61 +0.86 (+8.82%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$10.84 +0.24 (+2.21%)

As of 08/7/2026 07:34 PM Eastern

Compare

NNNN vs. LNTH, XENE, PTCT, BLTE, and CGON

Should you buy Anbio Biotechnology stock or one of its competitors? MarketBeat compares Anbio Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anbio Biotechnology include Lantheus (LNTH), Xenon Pharmaceuticals (XENE), PTC Therapeutics (PTCT), Belite Bio (BLTE), and CG Oncology (CGON).

How does Anbio Biotechnology compare to Lantheus?

Anbio Biotechnology (NASDAQ:NNNN) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

99.1% of Lantheus shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Lantheus had 31 more articles in the media than Anbio Biotechnology. MarketBeat recorded 31 mentions for Lantheus and 0 mentions for Anbio Biotechnology. Lantheus' average media sentiment score of 0.52 beat Anbio Biotechnology's score of 0.00 indicating that Lantheus is being referred to more favorably in the news media.

Company	Overall Sentiment
Anbio Biotechnology	Neutral
Lantheus	Positive

Lantheus has higher revenue and earnings than Anbio Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	176.56	$6.40M	N/A	N/A
Lantheus	$1.54B	4.26	$233.56M	$4.14	24.38

Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.09%. Given Lantheus' stronger consensus rating and higher possible upside, analysts plainly believe Lantheus is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lantheus	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Anbio Biotechnology has a beta of 5.4, indicating that its share price is 440% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

Lantheus has a net margin of 17.69% compared to Anbio Biotechnology's net margin of 0.00%. Lantheus' return on equity of 28.10% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Lantheus	17.69%	28.10%	14.35%

Summary

Lantheus beats Anbio Biotechnology on 12 of the 14 factors compared between the two stocks.

How does Anbio Biotechnology compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Anbio Biotechnology (NASDAQ:NNNN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Anbio Biotechnology's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.52%	-46.72%
Anbio Biotechnology	N/A	N/A	N/A

In the previous week, Xenon Pharmaceuticals had 13 more articles in the media than Anbio Biotechnology. MarketBeat recorded 13 mentions for Xenon Pharmaceuticals and 0 mentions for Anbio Biotechnology. Xenon Pharmaceuticals' average media sentiment score of 0.61 beat Anbio Biotechnology's score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Xenon Pharmaceuticals	Positive
Anbio Biotechnology	Neutral

Anbio Biotechnology has higher revenue and earnings than Xenon Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	816.67	-$345.91M	-$4.74	N/A
Anbio Biotechnology	$8.65M	176.56	$6.40M	N/A	N/A

Xenon Pharmaceuticals presently has a consensus price target of $77.13, indicating a potential upside of 21.74%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Xenon Pharmaceuticals is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Xenon Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.4, meaning that its share price is 440% more volatile than the broader market.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Xenon Pharmaceuticals beats Anbio Biotechnology on 9 of the 14 factors compared between the two stocks.

How does Anbio Biotechnology compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Anbio Biotechnology (NASDAQ:NNNN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

PTC Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.4, indicating that its stock price is 440% more volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than Anbio Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.54	$682.64M	-$0.58	N/A
Anbio Biotechnology	$8.65M	176.56	$6.40M	N/A	N/A

In the previous week, PTC Therapeutics had 12 more articles in the media than Anbio Biotechnology. MarketBeat recorded 12 mentions for PTC Therapeutics and 0 mentions for Anbio Biotechnology. PTC Therapeutics' average media sentiment score of 0.73 beat Anbio Biotechnology's score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
PTC Therapeutics	Positive
Anbio Biotechnology	Neutral

PTC Therapeutics currently has a consensus target price of $98.09, suggesting a potential upside of 33.80%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe PTC Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anbio Biotechnology has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. Anbio Biotechnology's return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
Anbio Biotechnology	N/A	N/A	N/A

Summary

PTC Therapeutics beats Anbio Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Anbio Biotechnology compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Anbio Biotechnology (NASDAQ:NNNN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Belite Bio presently has a consensus price target of $203.00, suggesting a potential upside of 24.50%. Given Belite Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Belite Bio is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anbio Biotechnology's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Anbio Biotechnology	N/A	N/A	N/A

Anbio Biotechnology has higher revenue and earnings than Belite Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Anbio Biotechnology	$8.65M	176.56	$6.40M	N/A	N/A

0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Belite Bio has a beta of -1.22, meaning that its stock price is 222% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.4, meaning that its stock price is 440% more volatile than the broader market.

In the previous week, Belite Bio had 7 more articles in the media than Anbio Biotechnology. MarketBeat recorded 7 mentions for Belite Bio and 0 mentions for Anbio Biotechnology. Belite Bio's average media sentiment score of 0.89 beat Anbio Biotechnology's score of 0.00 indicating that Belite Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Belite Bio	Positive
Anbio Biotechnology	Neutral

Summary

Belite Bio beats Anbio Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Anbio Biotechnology compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Anbio Biotechnology (NASDAQ:NNNN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Anbio Biotechnology has higher revenue and earnings than CG Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,639.56	-$160.99M	-$2.33	N/A
Anbio Biotechnology	$8.65M	176.56	$6.40M	N/A	N/A

Anbio Biotechnology has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Anbio Biotechnology's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-26.58%	-25.34%
Anbio Biotechnology	N/A	N/A	N/A

CG Oncology currently has a consensus target price of $83.18, suggesting a potential upside of 10.76%. Given CG Oncology's stronger consensus rating and higher probable upside, equities analysts clearly believe CG Oncology is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CG Oncology has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.4, suggesting that its stock price is 440% more volatile than the broader market.

In the previous week, CG Oncology had 25 more articles in the media than Anbio Biotechnology. MarketBeat recorded 25 mentions for CG Oncology and 0 mentions for Anbio Biotechnology. CG Oncology's average media sentiment score of 0.01 beat Anbio Biotechnology's score of 0.00 indicating that CG Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
CG Oncology	Neutral
Anbio Biotechnology	Neutral

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

CG Oncology beats Anbio Biotechnology on 8 of the 14 factors compared between the two stocks.

Get Anbio Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNNN vs. The Competition

Export

Metric	Anbio Biotechnology	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.53B	$5.82B	$7.02B	$13.01B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	N/A	24.26	271.11	25.19
Price / Sales	176.56	61.98	568.18	72.02
Price / Cash	238.39	33.10	71.81	50.72
Price / Book	50.52	5.70	13.25	6.22
Net Income	$6.40M	$148.58M	$3.45B	$342.66M
7 Day Performance	7.17%	4.75%	4.67%	4.41%
1 Month Performance	-4.84%	0.71%	-1.28%	-1.10%
1 Year Performance	N/A	4.93%	77.33%	23.99%

Anbio Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNNN Anbio Biotechnology	N/A	$10.61 +8.8%	N/A	N/A	$1.53B	$8.65M	N/A	27
LNTH Lantheus	2.9038 of 5 stars	$99.76 -2.8%	$109.71 +10.0%	+76.5%	$6.48B	$1.54B	23.98	1,193	News Coverage Earnings Report Analyst Downgrade
XENE Xenon Pharmaceuticals	2.3494 of 5 stars	$63.70 -1.9%	$77.20 +21.2%	+89.5%	$6.16B	$7.50M	N/A	210	Trending News Earnings Report Upcoming Earnings Analyst Forecast Analyst Revision
PTCT PTC Therapeutics	4.3909 of 5 stars	$73.70 -2.2%	$93.83 +27.3%	+61.5%	$6.13B	$1.73B	N/A	1,410	Analyst Downgrade Insider Trade Gap Down
BLTE Belite Bio	3.5915 of 5 stars	$153.34 -1.7%	$203.00 +32.4%	+133.3%	$6.12B	N/A	N/A	10	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NNNN) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anbio Biotechnology (NNNN) Competitors

NNNN vs. LNTH, XENE, PTCT, BLTE, and CGON

How does Anbio Biotechnology compare to Lantheus?

Summary

How does Anbio Biotechnology compare to Xenon Pharmaceuticals?

Summary

How does Anbio Biotechnology compare to PTC Therapeutics?

Summary

How does Anbio Biotechnology compare to Belite Bio?

Summary

How does Anbio Biotechnology compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anbio Biotechnology (NNNN) Competitors

NNNN vs. LNTH, XENE, PTCT, BLTE, and CGON

How does Anbio Biotechnology compare to Lantheus?

Do insiders & institutionals hold more shares of NNNN or LNTH?

Does the media refer more to NNNN or LNTH?

Which has better valuation & earnings, NNNN or LNTH?

Do analysts prefer NNNN or LNTH?

Which has more risk & volatility, NNNN or LNTH?

Is NNNN or LNTH more profitable?

Summary

How does Anbio Biotechnology compare to Xenon Pharmaceuticals?

Is XENE or NNNN more profitable?

Does the media prefer XENE or NNNN?

Which has stronger earnings and valuation, XENE or NNNN?

Do analysts prefer XENE or NNNN?

Which has more volatility & risk, XENE or NNNN?

Do insiders & institutionals have more ownership in XENE or NNNN?

Summary

How does Anbio Biotechnology compare to PTC Therapeutics?

Which has more risk and volatility, PTCT or NNNN?

Which has stronger earnings & valuation, PTCT or NNNN?

Does the media favor PTCT or NNNN?

Do analysts prefer PTCT or NNNN?

Is PTCT or NNNN more profitable?

Summary

How does Anbio Biotechnology compare to Belite Bio?

Do analysts prefer BLTE or NNNN?

Is BLTE or NNNN more profitable?

Which has stronger earnings & valuation, BLTE or NNNN?

Do insiders & institutionals hold more shares of BLTE or NNNN?

Which has more risk & volatility, BLTE or NNNN?

Does the media prefer BLTE or NNNN?

Summary

How does Anbio Biotechnology compare to CG Oncology?

Which has stronger valuation and earnings, CGON or NNNN?

Is CGON or NNNN more profitable?

Do analysts recommend CGON or NNNN?

Which has more risk and volatility, CGON or NNNN?

Does the media refer more to CGON or NNNN?

Do institutionals & insiders hold more shares of CGON or NNNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools